Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Bellezza

Showing results (41-50 of 105) with videos related to

Pageof 11
Sort By:
Oncotarget|August 25, 2015
Dyskerin and TERC expression may condition survival in lung cancer patientsMarianna Penzo, Vienna Ludovini, Davide Treré, et al.
Antioxidants (Basel, Switzerland)|February 27, 2026
Glyoxalase 2 Drives D-Lactate Oncometabolite Signaling to Promote Prostate Cancer Aggressiveness via FAK/Src ActivationDominga Manfredelli, Camilla Torcoli, Veronica Ceccarelli, et al.
Antioxidants (Basel, Switzerland)|September 27, 2025
PTEN/PKM2/ERα-Driven Glyoxalase 1 Overexpression Sustains PC3 Prostate Cancer Cell Growth Through MG-H1/RAGE Pathway Desensitization Leading to H<sub>2</sub>O<sub>2</sub>-Dependent KRIT1 DownregulationDominga Manfredelli, Camilla Torcoli, Marilena Pariano, et al.
Therapeutic Advances in Medical Oncology|June 14, 2017
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyBiagio Ricciuti, Sara Baglivo, Luca Paglialunga, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2010
Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancerTony Dhillon, Francesco A Mauri, Guido Bellezza, et al.
Tumori|December 16, 2006
Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profileAngelo Sidoni, Antonio Cavaliere, Guido Bellezza, et al.
Biomedical Materials (Bristol, England)|July 18, 2013
Evaluation of electrospun bioresorbable scaffolds for tissue-engineered urinary bladder augmentationCostantino Del Gaudio, Alberto Vianello, Guido Bellezza, et al.
Pathology, Research and Practice|February 7, 2006
Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profileAntonio Cavaliere, Massimo Scheibel, Guido Bellezza, et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology|August 21, 2009
HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significanceRachele Del Sordo, Francesca Angiero, Guido Bellezza, et al.
Journal of Thoracic Disease|December 23, 2017
Could thymomectomy be a reasonable option for non-myasthenic thymoma patients?Valentina Tassi, Silvia Ceccarelli, Cristina Zannori, et al.
Pageof 11

Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
Oncotarget|August 25, 2015
Dyskerin and TERC expression may condition survival in lung cancer patientsMarianna Penzo, Vienna Ludovini, Davide Treré, et al.
Antioxidants (Basel, Switzerland)|February 27, 2026
Glyoxalase 2 Drives D-Lactate Oncometabolite Signaling to Promote Prostate Cancer Aggressiveness via FAK/Src ActivationDominga Manfredelli, Camilla Torcoli, Veronica Ceccarelli, et al.
Antioxidants (Basel, Switzerland)|September 27, 2025
PTEN/PKM2/ERα-Driven Glyoxalase 1 Overexpression Sustains PC3 Prostate Cancer Cell Growth Through MG-H1/RAGE Pathway Desensitization Leading to H<sub>2</sub>O<sub>2</sub>-Dependent KRIT1 DownregulationDominga Manfredelli, Camilla Torcoli, Marilena Pariano, et al.
Therapeutic Advances in Medical Oncology|June 14, 2017
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyBiagio Ricciuti, Sara Baglivo, Luca Paglialunga, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2010
Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancerTony Dhillon, Francesco A Mauri, Guido Bellezza, et al.
Tumori|December 16, 2006
Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profileAngelo Sidoni, Antonio Cavaliere, Guido Bellezza, et al.
Biomedical Materials (Bristol, England)|July 18, 2013
Evaluation of electrospun bioresorbable scaffolds for tissue-engineered urinary bladder augmentationCostantino Del Gaudio, Alberto Vianello, Guido Bellezza, et al.
Pathology, Research and Practice|February 7, 2006
Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profileAntonio Cavaliere, Massimo Scheibel, Guido Bellezza, et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology|August 21, 2009
HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significanceRachele Del Sordo, Francesca Angiero, Guido Bellezza, et al.
Journal of Thoracic Disease|December 23, 2017
Could thymomectomy be a reasonable option for non-myasthenic thymoma patients?Valentina Tassi, Silvia Ceccarelli, Cristina Zannori, et al.
Pageof 11